COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

News and Announcements

All | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Displaying 1 - 10 of 10
Featuring Early-Career Investigators: Tung-Shing Mamie Lih

The following is the fifth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of glycoproteomics research with Tung-Shing Mamie Lih, PhD, an associate researcher at Johns Hopkins...


Characterizing the Molecular Landscape of Rare Renal Cell Carcinomas

In a recent study aiming to address knowledge gaps in non-clear cell renal cell carcinoma (non-ccRCC), researchers from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted an integrated multi-omic analysis of 48 non-ccRCC cases along with a previously...


Featuring Early-Career Investigators: Yifat Geffen

The following is the fourth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteogenomics research with Yifat Geffen, PhD, a postdoctoral researcher at the Broad Institute of MIT...


Characterizing the Evolution of Glioblastoma

Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite advancements in treatment and diagnosis. Tumor recurrence, developing in most patients (>90%), poses a major challenge due to tumor heterogeneity and limited understanding of post-treatment evolution. Previous studies have...


Presenting our 2024 CPTAC Meritorious Posters

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently held its Scientific Investigator Meeting in Portland, Oregon at the Oregon Health & Science University campus. The meeting featured key scientific and programmatic updates spanning multiple cancer types presented by consortium...


Proteomics in Focus: Insights from Dr. Nicole Tignor

The following is the third entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Nicole Tignor, PhD, Assistant Professor at the Icahn School of Medicine at...


Proteogenomic Characterization of Small Cell Lung Cancer: A Pathway to Personalized Medicine

Small cell lung cancer (SCLC) is an aggressive form of lung malignancy with historically poor prognoses and limited options for targeted treatment. The low availability of suitable biospecimens has also hampered large molecular characterization efforts.


Deciphering the Tumor Microenvironment: A Proteogenomic Pan-Cancer Analysis

The tumor microenvironment (TME) is a complex network which plays a crucial role in cancer progression and treatment responses. In a recently published Pan Cancer analysis, the Clinical Proteomic Tumor Analysis...


Advancing Personalized Treatment Strategies for Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. AML is known for its heterogeneity, presenting challenges in treatment and predicting patient outcomes.


Excellence in Proteomics Research: A Conversation with Jeffrey Whiteaker

The following is the second entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Jeffrey Whitaker, PhD, Director of Proteomics within the Paulovich Lab at...